All Dr Robert Scoffin (Cresset) articles
-
ArticleOvercoming the complexity of free energy perturbation calculations
In this article, Dr Robert Scoffin, Chairman and CEO at Cresset, explores FEP and its current challenges, and outlines how continuous advancements and strategic approaches are helping to drive the adoption of FEP methods in drug discovery.
-
ArticleHow the AI revolution can accelerate early drug discovery
Rob Scoffin and Matthew Habgood from solutions provider Cresset look to the future of drug discovery and the roles that artificial intelligence and machine learning could play.